Disc Medicine Inc
IRON60.790USD
-1.840-2.94%
收盤 09/19, 16:00（美東）報價延遲15分鐘
2.11B總市值
虧損本益比TTM
關於 Disc Medicine Inc 公司
Disc Medicine, Inc. 是一家臨牀階段生物製藥公司，專注於發現、開發和商業化針對患有嚴重血液病患者的新型治療方法。該公司的產品線包括用於治療紅細胞生成性卟啉症 (Eps)（包括紅細胞生成性原卟啉症 (EPP) 和 X 連鎖原卟啉症 (XLP)）和 Diamond-Blackfan 貧血症 (DBA) 的 bitopertin；用於治療骨髓纖維化貧血 (MF) 和慢性腎病貧血 (CKD) 的 DISC-0974，以及用於治療真性紅細胞增多症 (PV) 和其他血液病的 DISC-3405（以前稱爲 MWTX-003）。此外，其臨牀前項目還包括用於治療與炎症性疾病相關的貧血的 DISC-0998。Bitopertin 是該公司血紅素生物合成調節產品組合中的領先候選產品。該公司正在開發 DISC-3405，一種針對跨膜絲氨酸蛋白酶 6 的單克隆抗體，該抗體由 Mabwell Therapeutics, Inc. 授權。
公司簡介
公司代碼IRON
公司名稱Disc Medicine Inc
上市日期Aug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
員工數量84
證券類型Ordinary Share
年結日Aug 12
公司地址321 Arsenal Street, Suite 101
城市WATERTOWN
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02472
電話16176749274
網址https://www.discmedicine.com/
公司代碼IRON
上市日期Aug 12, 2020
CEODr. John D. Quisel, J.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Jean M. Franchi, CPA
Ms. Jean M. Franchi, CPA
Chief Financial Officer
Chief Financial Officer
--
-100.00%
Dr. William Savage, M.D., Ph.D.
Dr. William Savage, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Georges Gemayel, Ph.D.
Dr. Georges Gemayel, Ph.D.
Director
Director
--
--
Mr. Kevin J. Bitterman, Ph.D.
Mr. Kevin J. Bitterman, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Rahul Khara, Pharm.D.
Dr. Rahul Khara, Pharm.D.
Chief Legal Officer
Chief Legal Officer
36.87K
+162.73%
Ms. Pamela Stephenson
Ms. Pamela Stephenson
Chief Commercial Officer
Chief Commercial Officer
6.03K
-91.33%
Mr. Jonathan Yu
Mr. Jonathan Yu
Chief Operating Officer
Chief Operating Officer
--
--
Mr. William White, J.D.
Mr. William White, J.D.
Independent Director
Independent Director
--
--
Dr. Donald W. (Don) Nicholson, Ph.D.
Dr. Donald W. (Don) Nicholson, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Dr. Liam T. Ratcliffe, M.D., Ph.D.
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 9月3日 週三
更新時間: 9月3日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Access Industries, Inc.
10.24%
Fidelity Management & Research Company LLC
8.87%
Atlas Venture
6.18%
BlackRock Institutional Trust Company, N.A.
4.93%
Frazier Life Sciences Management, L.P.
4.76%
其他
65.03%
持股股東
持股股東
佔比
Access Industries, Inc.
10.24%
Fidelity Management & Research Company LLC
8.87%
Atlas Venture
6.18%
BlackRock Institutional Trust Company, N.A.
4.93%
Frazier Life Sciences Management, L.P.
4.76%
其他
65.03%
股東類型
持股股東
佔比
Investment Advisor
37.71%
Investment Advisor/Hedge Fund
18.24%
Hedge Fund
17.94%
Venture Capital
12.84%
Corporation
10.24%
Private Equity
9.90%
Research Firm
1.45%
Sovereign Wealth Fund
0.83%
Individual Investor
0.47%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
344
37.34M
107.82%
+1.72M
2025Q1
342
37.53M
108.38%
+1.77M
2024Q4
318
30.70M
90.70%
-5.11M
2024Q3
302
32.06M
106.93%
-4.30M
2024Q2
292
32.17M
107.84%
+2.52M
2024Q1
275
26.60M
108.28%
-1.06M
2023Q4
248
24.37M
101.48%
-1.80M
2023Q3
211
23.78M
99.79%
-259.52K
2023Q2
190
22.86M
100.53%
+3.93M
2023Q1
169
18.38M
96.84%
-1.35M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Access Industries, Inc.
3.56M
10.27%
--
--
Feb 27, 2025
Fidelity Management & Research Company LLC
3.05M
8.81%
+1.32M
+76.31%
Mar 31, 2025
Atlas Venture
2.38M
6.88%
-125.00K
-4.98%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.75M
5.06%
+219.74K
+14.35%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
1.75M
5.07%
--
--
Mar 31, 2025
RA Capital Management, LP
1.58M
4.55%
+1.58M
--
Mar 31, 2025
Janus Henderson Investors
1.42M
4.11%
+205.44K
+16.87%
Mar 31, 2025
T. Rowe Price Associates, Inc.
1.34M
3.87%
-36.42K
-2.65%
Mar 31, 2025
Wellington Management Company, LLP
2.34M
6.77%
+948.09K
+67.94%
Mar 31, 2025
OrbiMed Advisors, LLC
1.42M
4.09%
-370.55K
-20.75%
Mar 31, 2025
查看更多
持股ETF
更新時間: 9月6日 週六
更新時間: 9月6日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.93%
JPMorgan BetaBuilders US Small Cap Equity ETF
0.09%
Proshares Ultra Russell 2000
0.06%
Global X Russell 2000 ETF
0.06%
ProShares UltraPro Russell2000
0.06%
First Trust US Equity Opportunities ETF
0.06%
iShares Morningstar Small-Cap Value ETF
0.02%
Avantis US Small Cap Equity ETF
0.02%
Fidelity MSCI Health Care Index ETF
0.02%
Fidelity Nasdaq Composite Index ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.93%
JPMorgan BetaBuilders US Small Cap Equity ETF
佔比0.09%
Proshares Ultra Russell 2000
佔比0.06%
Global X Russell 2000 ETF
佔比0.06%
ProShares UltraPro Russell2000
佔比0.06%
First Trust US Equity Opportunities ETF
佔比0.06%
iShares Morningstar Small-Cap Value ETF
佔比0.02%
Avantis US Small Cap Equity ETF
佔比0.02%
Fidelity MSCI Health Care Index ETF
佔比0.02%
Fidelity Nasdaq Composite Index ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
公告日期
類型
比率
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
Dec 29, 2022
Merger
10→1
